Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioThrax: Phase III data

An open-label, U.S. Phase III trial in 200 healthy volunteers showed that 0.5 mL subcutaneous BioThrax on days

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE